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Introduction
The number of patients in dental surgical oral an-
ticoagulant treatment is increasing and this is
mainly due to the continuous increase of cardio-
vascular disease. The OAT is the golden goal for
the treatment and prevention of thromboembolic
disease and vascular type in general, such as in
carriers of prosthetic heart valves (1, 2) or valvu-
lar heart disease, in case of cardiac thrombosis
intracavitary, atrial fibrillation (3-6), atrial flutter
(7), acute myocardial infarction (8), dilated car-
diomyopathy (9), ischemic stroke (10), peripher-
al arterial disease (11), prevention of postopera-
tive thromboembolism (12), treatment of VTE
and prevention of relapse (13), and antiphospho-
lipid syndrome (14, 15). While patients with nor-
mal clotting parameters, have an INR between
0.7-1.2, the patients in TAO generally have val-
ues between 2 and 4, that indicate a more blood’s
fluidity. The risk of thrombosis is increased by a
decrease of the normal range. Before proceeding,
we have to assess the thromboembolic risk relat-
ed to the disease, and bleeding risks related to
surgery.
The treatments with bleeding’s risk include the
use of injectable anesthetics, tooth extractions,
placing implants osseointegrated, periodontal
surgery and periodontal curettage, minor surgery
and root canal therapy (16, 17). The knowledge
of the correct protocol outpatient management,
is a prerequisite for starting treatment. To date,
however, the management of these patients for
minor oral surgery (such as the osseointegrated
implants) is still a complex issue, with a strong
debate between the risk of uncontrolled bleeding
in case of no discontinuation of therapy or the
possibility of thromboembolic complications in
the case of suspension of the medication (18). In
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SUMMARY
Objectives. This work aims to assess the risks both thromboembolic that bleeding of a management protocol “non-con-
servative” in patients on oral anticoagulant therapy (OAT) to be undergoing implant surgery.
Materials and methods. We decided to take a surgical “non-conservative” protocol, to insert four implants in the aesthetic
zone, without using flapless surgery and the surgical template. In accordance with the hematologist, the value of INR is
lowered and warfarin was replaced with heparin low molecular weight, to have a better coagulation’s control.
Results. The modern guidelines impose a protocol of conservative management in patients with OAT, with minimally in-
vasive surgery, flapless, and use of surgical template to reduce the risk of uncontrolled bleeding. This, thanks to the team-
work between dentist and hematologist, thanks to careful adjustment of INR and the use of local haemostatic agents, were
not encountered any problems with bleeding or intra or postoperative.
Conclusion. Surgical treatment of patients with OAT is a real problem for the oral surgeon, to treat every time in associ-
ation with the hematologist. Applying this type of surgical procedure, different from today’s guidelines, in our experience
there were no post-operative complications (bleeding or bleeding); osseointegration has not been compromised and the
prosthetic rehabilitation was completed successfully.
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case report
this case report, we want show that it was possi-
ble the insertion of 4 plants, one of which is
post-extractive without the occurrence of post-
operative bleeding complications, thromboem-
bolic or bruising, with a non-flapless surgery
and without use of the drilling template. Thanks
to the teamwork between dentist and hematolo-
gist, the value of INR is lowered at 1.7, and war-
farin has been replaced with heparin low molec-
ular weight. The most important things, before
any oral surgery, is individualized a correct man-
agement protocol. Targeted’s protocol is neces-
sary in high tromboembolic risk patients to pre-
vent a thromboembolic event, at the expense of
a slightly increased risk of bleeding especially in
cases of minor oral surgery (18).
Materials and methods
At the Department of Special Pathology Odon-
tostomatology of the “Policlinico Tor Vergata”,
we treated a 68-year-old patient, sex M, with a
history of atrial fibrillation, in treatment with
warfarin and Almarythm. The RX orthopanoram-
ic evidents edentulous areas corresponding to the
elements 1.1, 1.2, 2.1, 2.2, 2.3 and the presence
of residual root of 1.3 with permanent rehabilita-
tion gold-porcelain-type “full-arch”. At the last
blood test, the value of INR is 3.
The fixed prosthetic restoration is fractured and
there are carious lesions in the cervical third
load of 1.3 (Figs. 1, 2).
We decided to rehabilitate the anterior area by
placing 4 implants in the position 1.2, 1.3, 2.2
and 2.3. In agreement with the hematologist, we
suspend the assumption of warfarin and we start-
ed the therapy with heparin low molecular
weight to correct altered coagulation’s values.
The INR at the time of surgery is 1,7. Heparin was
discontinued 10 hours before the surgical interven-
tion. In addition, the two days before the surgery,
the patient started antibiotic prophylaxis with 1 g
of amoxicillin and clavulanic acid every 12 hours.
Before starting the surgery we gave a rinse of 60
sec. with chlorhexidine digluconate 0.2%. The
two days before surgery, the patient started an-
tibiotic prophylaxis with 1 gr of amoxicillin and
clavulanate every 12 hours.
The surgery begins with preliminary anesthesia
with articaine 1/200.000 making a slow infusion.
We did the extraction of the residual root of 1.3,
followed by thorough bone’s toilet and removal
of any granulation tissues bleed easily (Fig. 3).
We did crestal incision, near the palatal side,
without flap-less surgery and surgical template
(to reduce time and costs of labor) (Fig. 4).
We did the mechanical preparation, using Win-
six’s incremental pre-calibrated drills of length
13 mm, maintaining an under-preparation of 2
mm in each implant’s locus, due to the compact-
ness of bone type D2. We insert a post-extraction
implant Winsix TTx Micro Rough Surface inter-
nal hex conical, lenght 13 mm and diameter 4.5
mm in area 1.3, inserting the vestibular cortical
Figure 1
Rx Orthopanoramic before treatment.
Figure 2
Intraoral view before treatment.
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granules obtained by milling. In the other areas
we opted for implants Winsix TTx 13 mm diam-
eter and 3.8 mm, placing the screw cap Winsix
and sutured with Vycril 3/0 (Fig. 5).
We irrigated the surgical field with tranexamic
acid solution and applied where necessary, fibrin
glue. After 30 minutes, the bleeding was com-
pletely absent. Because it was the aesthetic zone,
we proceed to the reposition of prosthetic
restoration, previously modified, using the
stumps remaining 1.5, 2.4 and 2.5. After 10
hours of surgery, the heparin is administered
again, and then suspended entirely, when the
INR values were higher than 2.0 for two times,
as suggested by Rossi & Magrella (19). After
two samples with an INR> 2, the warfarin thera-
py was taken up only.
The timing phasing is maintained until the com-
plete osseointegration of the implant fixture. We
decided to maintain on-site restoration in the es-
thetic zone, for 4 months. The patient decided,
for economic issues, to finalize the work with el-
ements in reinforced resin, rather than ceramic
(Figs. 6, 7, 8).
The discharge of the patient is not made before
60 minutes of the end of the surgery (to verify the
absence of bleeding) and we proceeded to the ap-
plication of an ice pack for 3-4 hours. For the 3
days after surgery, patient followed a liquid diet
Figure 3
The maxilla after extraction of residual root 1.3.
Figure 4
Crestal incision before the implants’ insertion.
Figure 5
Winsix implants and screws cap in position 1.3 and 1.4.
Figure 6
After 4 months the placement of the healing screws.
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and cold for the 4 following weeks, soft and
warm. We prescribed oral rinse with 10 mL of
aqueous solution of tranexamic acid for 2 min-
utes, repeated 4 times a day for 7 days. He could-
n’t eat or drink for about an hour after rinsing and
oral rinses with chlorhexidine digluconate 0.12%
twice a day (morning and evening) as suggested
by Gonty (20). The anti-inflammatory therapy if
required, was based on the use of paracetamol.
Results
All patients should be directed to their hematol-
ogist for adjustment of therapy, before any inva-
sive dental procedure. Applying this type of
“non-conservative” protocol, associated with the
adjustment of INR, there were no post-operative
complications in our case (uncontrolled bleeding
or thromboembolic phenomenon).
Osseointegration was minimally impaired and
prosthetic rehabilitation was completed suc-
cessfully.
Discussion
For the dental treatment of patients with OAT, is
important to value the surgical risk and the pos-
sibility of thromboembolism and, it is important
to perform a careful history and thorough eval-
uation of INR (21). Garcia et al. in 2008 pub-
lished an important prospective study on the
risk of thromboembolism after a brief suspen-
sion of the OAT, reporting an incidence of
thromboembolic events of 0.5%, in a follow-up
period of 30 days (22). In the same study is al-
so emphasized as the majority of postoperative
bleeding begins at a distance of 2-3 days after
surgery, by the action of plasminogen activa-
tors, resulting in clot lysis (crankcase). The sur-
gery and local anesthesia should be performed
in the least traumatic way, otherwise it would
cause massive bruising. With regard to the
guidelines in oral surgery in patients with OAT,
the review by the American College of Chest
Physicians recommends always co-administra-
tion of a pro-haemostatic local agent (23).
Guidelines doesn’t do differences between big
or small surgery. In agreement with Scully et al.
(2007), the trauma for the positioning of a plant,
is the same of the extraction of 3 teeth, provid-
ed that these processes do not involve collection
of autologous bone grafts, the execution of large
flaps or the placement of installations in sites
where there is a risk during the preparation of
the osteotomy to extend outside of the bone
marrow (24). The reduction in the perioperative
period of warfarin dosing or discontinuation of
anticoagulant treatment 2 or 3 days before oral
surgery procedure is a strategy widely used. It
aims to decrease the value of INR with the pre-
Figure 7
The provisional elements in reinforced resin before their fix-
ing with screws.
Figure 8
Rx Orthopanoramic after treatment.
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diction that in the next 48-72 hours, will be in
the range 1.5-2.1 (25). The complete suspension
of the OAT is often recommended to reduce the
risk of post-operative bleeding, resulting in 4
days the return to a state of coagulation of a typ-
ical normal subject. This strategy may, however,
expose the patient to increased risk of throm-
boembolic events (26). The need to prevent an
attack of thromboembolism, in patients, classi-
fied as high risk of thromboembolism, should
dictate the use of a Bridging Therapy‘s protocol
for the perioperative management, regardless of
the risk of bleeding, especially in cases of minor
oral surgery.
It’s been shown from Madrid and Sanz in 2009
that patients on OAT (with INR between 2 and 4)
who do not suspend the drug, do not present an
increased risk of postoperative bleeding com-
pared with patients who discontinue oral appli-
cation; also the application of local hemostatic
agents is very effective to prevent postoperative
bleeding. The comparison carried out by the au-
thors, among the various hemostatic agents
(rinses with tranexamic acid, gelatin sponges or
fibrin glue) showed a similar positive effect in
the results (18).
Conclusions
Surgical treatment of patients with OAT is a real
problem for the oral surgeon. Although there is a
theoretical risk of hemorrhage following sur-
gery, using our protocol based on the suspension
of warfarin and the beginning of heparin, the
risk of bleeding appears to be minimal and easi-
ly controlled by the use of local hemostatic.
This risk seems to be minimal and the bleeding
controllable through the use of local measures of
hemostasis. This risk is, however, much less im-
portant than the risk of thromboembolism asso-
ciated with the discontinuation of therapy (27).
Based on the above, we can therefore say that
the suspension of OAT is not recommended in
cases of minor oral surgery, such as a single
tooth extraction, predisposing the subject to
greater risks than benefits. The application of lo-
cal hemostatic agents is always recommended
after each surgery (e.g. tranexamic acid 4.8% 10
ml, 4 times/day for 2 days), gelatin sponges con-
taining thrombin or biological adhesives: all
with the same effective power in the control of
postoperative bleeding. We can also conclude
that despite the modern management recom-
mending a “conservative” protocols of the pa-
tient, in our case we have adopted a “normal”
management protocol, so without using flapless
surgery and surgical template, and found no
bleeding or thromboembolic phenomena in the
post-operative thanks to the careful preliminary
assessment and the teamwork between dentist
and hematologist. In addition, we can reduce the
timing of work, as well as costs of treatment,
without the use of surgery flapless and/or surgi-
cal template. The placement of osseointegrated
implants is not absolutely contraindicated in pa-
tients taking anticoagulants, but always we
adopt an appropriate management protocol in
accordance with the modern guidelines.
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